PUNE, India, May 16, 2018 /PRNewswire/ --
According to a new market research report "Neuroscience Antibodies & Assays Market by Product (Reagent (Media, Sera, Stain, Enzymes, Probe), Instruments), Technology (Immunoassay (Elisa), Molecular Diagnostics), Application (IVD) & End User (Research Institute, Hospital) - Global Forecast to 2023", the global market is expected to reach USD 4.18 Billion by 2023 from USD 2.57 Billion in 2018, at a CAGR of 10.2%.
(Logo: https://mma.prnewswire.com/media/660509/MarketsandMarkets_Logo.jpg )
Browse 103 market data Tables and 35 Figures spread through 157 Pages and in-depth TOC on"Neuroscience Antibodies & Assays Market"
https://www.marketsandmarkets.com/Market-Reports/neuroscience-antibodies-assays-market-129888612.html
Early buyers will receive 10% customization on this report
Growth in Neuroscience Antibodies and Assays Market is driven by the rising incidence of neurological diseases, increasing investments in neuroscience research, and growth in the pharmaceutical and biotechnology industries.
Based on product, consumables segment is expected to dominate the Neuroscience Antibodies and Assays Market in 2018
Based on product, the Neuroscience Antibodies and Assays Market are segmented into consumables and instruments. The consumables segment is expected to account for the largest market share in 2018 and is projected to register the highest CAGR during the forecast period. The consistent usage of consumables and their frequent purchases, and rising government initiatives in the genomics and proteomics research sector are the major factors supporting the growth of the consumables segment.
The immunoassays/immunochemistry segment is expected to dominate the market in 2018
Based on technology, the Neuroscience Antibodies and Assays Market are segmented into immunoassays/immunochemistry, molecular diagnostics, clinical chemistry, and other technologies. In 2018, immunoassays/immunochemistry segment is expected to account for the largest share of the neuroscience antibodies and assays market. The large share of this segment is attributed to the development of novel antibodies and assays for immunoassay techniques, technological developments in immunoassays, and rising government initiatives in the genomics and proteomics research sector.
Based on application, the in vitro diagnostics segment is expected to register the highest CAGR during the forecast period
Based on application, the Neuroscience Antibodies and Assays Market are segmented into research, drug discovery and development, and in vitro diagnostics. The in vitro diagnostics applications segment is expected to register the highest CAGR during the forecast period. The high growth of this segment is attributed to the increasing incidence and prevalence of neurological diseases across the globe, especially in developing countries.
Ask for PDF Brochure @https://www.marketsandmarkets.com/pdfdownload.asp?id=129888612
North America to dominate the neuroscience antibodies and assays market
In 2018, North America is expected to dominate the market followed by Europe. The large share of this geographical segment is attributed to the increasing investments for the development of structure-based drug designs, growing research in the field of genomics and proteomics, rising demand for high-quality research tools for data reproducibility, and the focus of stakeholders on research projects involving proteins, associated biomolecules, and genes.
The Neuroscience Antibodies and Assays Market is fragmented, with the presence of several large as well as emerging players. In 2017, Thermo Fisher Scientific (US), Abcam (UK), Bio-Rad (US), and Merck KGaA (Germany) were the leading players in the neuroscience antibodies and assays market. Other major players include BioLegend (US), Cell Signaling Technology (US), F. Hoffmann-La Roche (Switzerland), GenScript (China), Rockland Immunochemicals (US), Santa Cruz Biotechnology (US), Siemens (Germany), and Tecan (Switzerland).
Know more about the Neuroscience Antibodies & Assays Market
https://www.marketsandmarkets.com/Market-Reports/neuroscience-antibodies-assays-market-129888612.html
About MarketsandMarkets
MarketsandMarkets provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 5000 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets for their painpoints around revenues decisions.
Our 850-fulltime analyst and SMEs at MarketsandMarkets are tracking global high growth markets following the "Growth Engagement Model - GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets's flagship competitive intelligence and market research platform, "RT" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
Contact:
Mr. Salgarkar
MarketsandMarkets INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
sales@marketsandmarkets.com
Connect with us on LinkedIn @ http://www.linkedin.com/company/marketsandmarkets
